In addition to the MAPK pathway, deregulation of cyclin-dependent kinase 4 and 6 (CDK4/6) activity frequently occurs in melanoma, mainly due to inactivation of the CDK4/6 inhibitor p16INK4A via gene deletion, somatic mutation, or promoter hypermethylation [6,7]. Here, CDK4 is linked to melanoma.